

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR |
|----------------------|-----|-----------------|------------|-------------------|---|
| | A13 | 60/458,193 | 3/28/2003 | Renzi | |
| | A14 | 09/290,938 | 4/13/1999 | Brines et al. | |
| | A15 | 09/547,220 | 4/11/2000 | Brines et al. | |
| | A16 | 09/716,963 | 11/21/2000 | Brines et al. | |
| | A17 | 09/718,829 | 11/21/2000 | Brines et al. | |
| | A18 | 11/880,275 | 7/19/2007 | Brines et al. | |
| | A19 | 2002/0052309 | 5/02/2002 | Anagnostou et al. | |
| | A20 | 2002/0061849 | 5/23/2002 | Nielsen et al. | |
| | A21 | 2002/0081734 | 6/27/2002 | Choi et al. | |
| | A22 | 2002/0160460 | 10/31/2002 | Paulson et al. | |
| | A23 | 2003/0003529 | 1/2/2003 | Bayer | |
| | A24 | 2003/0040037 | 2/27/2003 | Bayer | |
| | A25 | 2003/0072737 | 4/17/2003 | Brines et al. | |
| | A26 | 2003/0089468 | 5/15/2003 | Kettunen et al. | |
| | A27 | 2003/0104988 | 6/5/2003 | Brines et al. | |
| | A28 | 2003/0120045 | 6/26/2003 | Bailon | |
| | A29 | 2003/0134798 | 7/17/2003 | Brines et al. | |
| | A30 | 2004/0009902 | 1/15/2004 | Boime | |
| | A31 | 2004/0091961 | 5/13/2004 | Evans et al. | |
| | A32 | 2004/0122216 | 6/24/2004 | Nielsen et al. | |
| | A33 | 2004/0209812 | 10/21/2004 | Farrell et al. | |
| | A34 | 2004/0214236 | 10/28/2004 | Brines et al. | |
| | A35 | 2005/0106722 | 5/19/2005 | Jones et al. | |
| | A36 | 2005/0164386 | 7/28/2005 | Uytendhaag et al. | |
| | A37 | 2005/0170463 | 8/04/2005 | Bout et al. | |
| | A38 | 2005/0176627 | 8/11/2005 | Cerami et al. | |
| | A39 | 2006/0099685 | 5/11/2006 | Yallop et al. | |
| | A40 | 2006/0216757 | 9/28/2006 | Brines et al. | |
| | A41 | 2007/0054394 | 3/08/2007 | Bout et al. | |

EXAMINER

NYI-4228193/1

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|--|--------------------------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. 10165-037-999 | APPLICATION NO. 10/520,140 |
| | APPLICANT Brines et al. | |
| | FILING DATE January 3, 2005 | ART UNIT 1647 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----|-----------------|------------|------------------|---|
| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR |
| | A42 | 2007/0117742 | 5/24/2007 | Opstelten et al. | |
| | A43 | 2007/0129293 | 6/07/2007 | Coleman et al. | |
| | A44 | 2007/0231860 | 10/04/2007 | Uytdehaag et al. | |
| | A45 | 2007/0275439 | 11/29/2007 | Opstelten | |
| | A46 | 2007/0298031 | 12/27/2007 | Brines et al. | |
| | A47 | 2007/0298464 | 12/27/2007 | Opstelten et al. | |
| | A48 | 2008/0014193 | 1/17/2008 | Brines et al. | |
| | A49 | 2008/0032922 | 2/07/2008 | Opstelten et al. | |
| | A50 | 2008/0050403 | 2/28/2008 | Marzio et al. | |
| | A51 | 2008/0305990 | 12/11/2008 | Brines et al. | |
| | A52 | 2009/0004202 | 1/01/2009 | Brines et al. | |
| | A53 | 2009/0136519 | 5/28/2009 | Brines et al. | |
| | A54 | 2009/0233844 | 9/17/2009 | Brines et al. | |
| | A55 | 2009/0258821 | 10/15/2009 | Cerami et al. | |
| | A56 | 4,343,782 | 8/10/1982 | Shapiro | |
| | A57 | 4,992,419 | 2/12/1991 | Woog et al. | |
| | A58 | 5,278,065 | 6/11/1994 | D'Andrea | |
| | A59 | 5,292,654 | 3/08/1994 | Yoshimura | |
| | A60 | 5,354,934 | 10/11/1994 | Pitt et al. | |
| | A61 | 5,591,713 | 1/07/1997 | Igari et al. | |
| | A62 | 5,604,198 | 2/18/1997 | Poduslo et al. | |
| | A63 | 5,750,376 | 5/12/1998 | Weiss et al. | |
| | A64 | 5,763,198 | 6/09/1998 | Hirth et al. | |
| | A65 | 5,824,672 | 10/20/1998 | Simpkins et al. | |
| | A66 | 5,997,865 | 12/7/1999 | Bennett et al. | |
| | A67 | 6,048,971 | 4/11/2000 | Sytkowski et al. | |
| | A68 | 6,071,970 | 6/06/2000 | Mueller et al. | |
| | A69 | 6,103,526 | 04/15/2005 | Smith et al. | |
| | A70 | 6,121,246 | 9/19/2000 | Isner | |

| | |
|---|------------------------|
| EXAMINER NY14228197v1 | DATE CONSIDERED |
| *EXAMINER Initial of reference considered, whether or not citation is in conformance with MPPEP 609 . Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | |
|---|-----------------|-----------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO | APPLICATION NO. |
| | 10165-037-999 | 10/520,140 |
| | APPLICANT | |
| | Brines et al. | |
| | FILING DATE | ART UNIT |
| | January 3, 2005 | 1647 |

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR |
|-------------------|-----------------|------------|------------------|---|
| | A71 6,153,407 | 11/28/2000 | Sytkowski et al. | |
| | A72 6,200,567 | 3/13/2001 | Lopez et al. | |
| | A73 6,242,570 | 6/05/2001 | Sytkowski | |
| | A74 6,291,661 | 09/18/2001 | Graddis et al. | |
| | A75 6,340,742 | 1/22/2002 | Burg et al. | |
| | A76 6,399,336 | 6/4/2002 | Paulson et al. | |
| | A77 6,440,932 | 8/27/2002 | Lehmann et al. | |
| | A78 6,475,717 | 11/05/2002 | Enssle et al. | |
| | A79 6,489,293 | 12/3/2002 | Sytkowski et al. | |
| | A80 6,521,245 | 2/18/2003 | Zaharia | |
| | A81 6,583,272 | 6/24/2003 | Bailon | |
| | A82 6,645,522 | 11/11/2003 | Naeff et al. | |
| | A83 6,784,154 | 8/31/2004 | Westenfelder | |
| | A84 6,855,544 | 2/15/2005 | Hateboer et al. | |
| | A85 6,930,086 | 8/16/2005 | Tischer | |
| | A86 7,053,184 | 5/30/2006 | Lee | |
| | A87 7,087,224 | 8/8/2006 | Kay et al. | |
| | A88 7,091,326 | 8/15/2006 | Lee et al. | |
| | A89 7,098,318 | 8/29/2006 | Lee et al. | |
| | A90 7,214,532 | 5/08/2007 | Stern et al. | |
| | A91 7,220,555 | 5/22/2007 | Paulson et al. | |
| | A92 7,262,166 | 8/28/2007 | Kinstler et al. | |
| | A93 7,297,680 | 11/20/2007 | Opstelten et al. | |
| | A94 7,300,915 | 11/27/2007 | Campana et al. | |
| | A95 7,300,916 | 11/27/2007 | Yasuda et al. | |
| | A96 7,304,031 | 12/04/2007 | Opstelten et al. | |
| | A97 7,309,687 | 12/18/07 | Brines et al. | |
| | A98 7,345,019 | 3/18/08 | Brines et al. | |
| | A99 7,410,941 | 8/12/08 | Brines et al. | |

| | |
|---|------------------------|
| EXAMINER NY1-4228197v1 | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.
10165-037-999

APPLICATION NO.
10/520,140

APPLICANT
Brines et al.

FILING DATE
January 3, 2005

ART UNIT
1647

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR |
|----------------------|-----------------|-----------|---------------|---|
| A100 | 7,504,248 | 3/17/2009 | Marzio et al. | |
| A101 | 6,747,002 | 6/8/2004 | Cheung et al. | |

FOREIGN PATENT DOCUMENTS

| | FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN) | DATE | NAME | PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR | T |
|-----|---|------------|---|---|---|
| B14 | CA 2,294,448 | 12/30/1998 | Roche Diagnostics GmbH | | |
| B15 | DE 198 57 609 | 6/15/00 | Ehrenreich and Gleiter (w/English abstract) | | |
| B16 | EP 0640619 | 1/3/1995 | Amgen Inc. | | |
| B17 | EP 0668351 | 8/23/1995 | Amgen, Inc. | | |
| B18 | EP 0883343 | 4/24/1997 | St. Elizabeth's Medical Center of Boston, Inc. | | |
| B19 | EP 1064951 | 1/03/2001 | F. Hoffmann-La Roche AG | | |
| B20 | EP 1440157 | 5/8/2003 | Crucell Holland B.V. | | |
| B21 | EP 1625858 | 2/15/2006 | St. Elizabeth's Medical Center of Boston, Inc. | | |
| B22 | EP 1633383 | 3/15/2006 | Janssen Pharmaceutica N.V. | | |
| B23 | EP 1831381 | 7/6/2006 | Crucell Holland B.V. | | |
| B24 | EP 1889627 | 2/20/2008 | Niigata TLO Corporation | | |
| B25 | FR 2 823 220 | 10/11/2002 | Genodysee (w/English abstract) | | |
| B26 | JP-05092928 | 4/16/93 | Snow Brand Milk Prod Co., Ltd., (w/English abstract) | | |
| B27 | WO 1985/002610 | 6/20/1985 | Kirin-Amgen, Inc. | | |
| B28 | WO 1986/003520 | 6/19/1986 | Genetics Institute, Inc. | | |
| B29 | WO 1990/011354 | 10/4/1990 | Institut Pasteur (w/English abstract) | | |
| B30 | WO 1991/005867 | 5/2/1991 | Amgen Inc. | | |
| B31 | WO 1991/006667 | 5/16/1991 | Cell Genesys, Inc. | | |
| B32 | WO 1991/009955 | 7/11/1991 | Applied Research Systems, ARS Holding MV | | |
| B33 | WO 1993/009222 | 5/13/1993 | Transkaryotic Therapies, Inc. | | |
| B34 | WO 1993/025221 | 12/23/1993 | Alkermes Controlled Therapeutics | | |

EXAMINER
NY14228197.1

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.
10165-037-999

APPLICATION NO.
10/520,140

APPLICANT
Brines et al.

FILING DATE
January 3, 2005

ART UNIT
1647

FOREIGN PATENT DOCUMENTS

| | | FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN) | DATE | NAME | PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR | T |
|--|-----|--|------------|--|---|---|
| | B35 | WO 1994/012650 | 6/9/1994 | Transkaryotic Therapies, Inc. | | |
| | B36 | WO 1995/005465 | 2/23/1995 | Amgen Inc. | | |
| | B37 | WO 1995/031560 | 11/23/1995 | Transkaryotic Therapies, Inc. | | |
| | B38 | WO 1997/008307 | 3/6/1997 | Il Dong Pharmaceutical Co. Ltd. | | |
| | B39 | WO 1997/014307 | 4/24/1997 | St. Elizabeth's Medical Center of Boston, Inc. | | |
| | B40 | WO 1998/010650 | 3/19/1998 | East Carolina University | | |
| | B41 | WO 1998/058660 | 12/30/1998 | Boehringer Mannheim GMBH (w/English abstract) | | |
| | B42 | WO 1999/021966 | 5/06/1999 | Neurospheres Holdings Ltd. | | |
| | B43 | WO 2000/024893 | 5/4/2000 | Amgen, Inc. | | |
| | B44 | WO 2000/032772 | 6/8/2000 | Eli Lilly & Co. | | |
| | B45 | WO 2000/061164 | 10/19/00 | Kenneth S. Warren Laboratories | | |
| | B46 | WO 2001/002017 | 1/11/2001 | F. Hoffmann-La Roche AG | | |
| | B47 | WO 2001/081405 | 11/1/2001 | Amgen Inc. | | |
| | B48 | WO 2001/087329 | 11/22/2001 | F. Hoffmann-La Roche AG | | |
| | B49 | WO 2002/000721 | 1/3/2002 | Zymogenetics, Inc. | | |
| | B50 | WO 2002/014356 | 2/21/2002 | Althoff, Claudia | | |
| | B51 | WO 2002/049673 | 6/27/2002 | F. Hoffmann-La Roche AG | | |
| | B52 | WO 2002/053580 | 7/11/02 | Kenneth S. Warren Institute, Inc. | | |
| | B53 | WO 2003/029291 | 4/10/2003 | F. Hoffmann-La Roche AG | | |
| | B54 | WO 2003/038100 | 5/8/2003 | Cruceil Holland B.V. | | |
| | B55 | WO 2003/089468 | 10/30/2003 | Cruceil Holland B.V. | | |
| | B56 | WO 2004/003176 | 1/8/04 | The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S | | |
| | B57 | WO 2004/004656 | 1/15/04 | The Kenneth S. Warren Institute, Inc. | | |
| | B58 | WO 2004/022577 | 3/18/2004 | Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc. | | |
| | B59 | WO 2004/087063 | 10/14/2004 | Janssen Pharmaceutica NV | | |
| | B60 | WO 2004/096148 | 11/11/04 | The Kenneth S. Warren Institute, Inc. | | |
| | B61 | WO 2004/112693 | 12/29/2004 | Kenneth S. Warren Institute, Inc. | | |
| | B62 | WO 2005/025606 | 3/24/05 | Warren Pharmaceuticals, Inc.; | | |

EXAMINER
NYI-422819751

DATE CONSIDERED

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|------------------|-----------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 10165-037-999 | 10/520,140 |
| | APPLICANT | |
| | Brines et al. | |
| | FILED DATE | ART UNIT |
| | January 3, 2005 | 1647 |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--|----------------|-----------------------------------|---|--|---|
| | FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN) | DATE | NAME | PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR | | T |
| | | | Kenneth S. Warren Institute, Inc. | | | |
| | B63 | WO 2005/032467 | 4/14/05 | Warren Pharmaceuticals, Inc. | | |
| | B64 | WO 2005/084364 | 9/15/05 | The Kenneth S. Warren Institute, Inc. | | |
| | B65 | WO 2005/117927 | 12/15/05 | The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S | | |
| | B66 | WO 2006/002646 | 1/12/06 | H. Lundbeck A/S | | |
| | B67 | WO 2006/014349 | 2/9/06 | The Kenneth S. Warren Institute, Inc., et al. | | |
| | B68 | WO 2006/014466 | 2/9/06 | The Kenneth S. Warren Institute, Inc.; Lundbeck, H., A/S | | |
| | B69 | WO 2006/070011 | 7/6/2006 | Cruce Holland B.V. | | |
| | B70 | WO 2006/129755 | 12/7/2006 | Nilgato TLO Corporation (w/English Abstract) | | |
| | B71 | WO 1994/028024 | 12/8/1994 | Enzon, Inc. | | |

| NON PATENT LITERATURE DOCUMENTS | | | | | | |
|---------------------------------|------|--|--|--|--|---|
| Examiner Initials | | (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.) | | | | T |
| | C118 | Patent Interference No. 105,500 Ehrenreich v. Brines: Judgment Paper I, Declaration, Brines clean copy of claims, and Ehrenreich clean copy of claims (10/02/06) | | | | |
| | C119 | ABDELRAHMAN, 2004, "Erythropoietin attenuates the tissue injury associated with hemorrhagic shock an myocardial ischemia," Shock, Vol. 22(1), pp 63-69 | | | | |
| | C120 | AGNELLO et al., 2002, "Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis," Brain Research 952:128-134 | | | | |
| | C121 | AKHTAR et al., 1999, "Conformational study of N(epsilon)-(carboxymethyl)lysine adducts of recombinant alpha-crystallins," Current Eye Research 18:270-276 | | | | |
| | C122 | ALAFACI et al., 2000, "Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following Experimental Subarachnoid Hemorrhage," Eur. J. Phar., 406:219-225. | | | | |
| | C123 | ANAGNOSTOU et al., 1994, "Erythropoietin receptor mRNA expression in human endothelial cells," Proc. Natl. Acad. Sci. USA 91:3974-3978 | | | | |
| | C124 | ANDO et al., 1996, "Autonomic dysfunction and anemia in neurologic disorders", J. Autonomic Nervous Syst. 61:145-148 | | | | |
| | C125 | ANNABLE et al., 1972, "The Second International Reference Preparation of Erythropoietin, Human, Urinary, for Bioassay," Bull. Org. Mond. Sante, 47:99-112. | | | | |
| | C126 | ARZNEIMITTELKOMMISSION DER DEUTSCHEN ARZTESCHAFT, 2004, "Empfehlungen zur Therapie der Demenz," Arzneiverordnung in der Praxis, Band 31, Sonderheft 4 (w/English abstract) | | | | |
| | C127 | ASHWELL et al., 1978, "A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated Glycoproteins," Meth. Enzymol., 50:287-291. | | | | |

| | |
|---|------------------------|
| EXAMINER NYI-4228197v1 | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-037-999

APPLICATION NO

10/520,140

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

| | | |
|------|---|--|
| C128 | AY et al., 1999, "Potential usefulness of basic fibroblast growth factor as a treatment for stroke," <i>Cerebrovascular Disease</i> 9:131-135 | |
| C129 | BANY-MOHAMMED et al., 1996, "Recombinant human erythropoietin: possible role as an antioxidant in premature rabbits," <i>Pediatric Res.</i> 40(3):381-387 | |
| C130 | BARBER et al., 2001, "De novo design of cytokine-based alpha helical binding domains display cytotoxic activity," <i>Blood</i> 98(11, part 2):132b-133b Abstract 4193 | |
| C131 | BARBER et al., 1994, "Erythropoietin and interleukin-2 activate distinct JAK kinase family members," <i>Mol. Cell. Biol.</i> 14(10):6506-6514 | |
| C132 | BARBONE et al., 1997, "Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-function relationships," <i>J. Biol. Chem.</i> 272(8):4985-4992 | |
| C133 | BARRON et al., 1994, "Alternatively spliced mRNAs encoding soluble isoforms of the erythropoietin receptor in murine cell lines and bone marrow," <i>Gene</i> 147:263-8 | |
| C134 | BASKAYA et al., 1997, "The biphasic opening of the blood-brain barrier in the cortex and hippocampus after traumatic brain injury in rats," <i>Neuroscience Lett.</i> 226:33-36 | |
| C135 | BAZAN, 1989, "A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain," <i>Biochem. Biophys. Res. Commun.</i> 164(2):788-795 | |
| C136 | BELAYEV et al., 1996, "Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats," <i>Brain Research</i> 739:88-96 | |
| C137 | BENIT et al., 1993, "The 'WS motif' common to v-mpl and members of the cytokine receptor superfamily is dispensable for myeloproliferative leukemia virus pathogenicity," <i>Oncogene</i> 8:787-790 | |
| C138 | BENYO et al., 1999, "Expression of erythropoietin receptor by trophoblast cells in the human placenta," <i>Biol. Reprod.</i> 60:861-870 | |
| C139 | BERNAT et al., 2003, "Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization," <i>PNAS Vol.</i> 100(3):952-57 | |
| C140 | BERNAUDIN et al., 2000, "Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain," <i>Glia</i> 30:271-278 | |
| C141 | BESARAB et al., 1998, "The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin," <i>New England Journal of Medicine</i> 339(9):584-590 | |
| C142 | BIANCHI et al., 2004, "Erythropoietin both protects from and reverses experimental diabetic neuropathy," <i>PNAS, Vol. 101, pp.</i> 823-828 | |
| C143 | BICKEL et al., 1993, "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery," <i>Proc Natl Acad Sci USA</i> 90:2618-22 | |
| C144 | BICKEL et al., 1994, "In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium," <i>J Histochem Cytochem. Vol.</i> 42(11):1493-7 | |
| C145 | BOADO et al., 1998, "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS," <i>J Pharm Sci. Vol.</i> 87(11):1308-15 | |
| C146 | BOGER and GOLDBERG, 2001, "Cytokine receptor dimerization and activation: prospects for small molecule agonists," <i>Bioorg. & Med. Chem.</i> 9:557-562 | |
| C147 | BOGOYEVITCH, 2004, "An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection," <i>Cardiovascular Research, Vol.</i> 63, pp. 208-16 | |
| C148 | BOISSEL et al., 1993 "Erythropoietin structure-function relationships," <i>J. Biol. Chem. Vol.</i> 268(21):15983-15993 | |
| C149 | BONSI et al., 1997, "An erythroid and megakaryocytic common precursor cell line (B1647) expressing both c-mpl and erythropoietin receptor (Epo-R) proliferates and modifies globin chain synthesis in response to megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo)," <i>Br. J. Haematol.</i> 98:540-559 | |

EXAMINER
NYI-4228197x1

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO

10165-037-999

APPLICATION NO

10/520,140

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

| | |
|------|--|
| C150 | BOUDOT et al., 1999, "Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement of phospholipase c-gamma2," J. Biol. Chem. 274(48):33966-33972 |
| C151 | BRIGGS et al., 1974, "Hepatic Clearance of Intact and Desialylated Erythropoietin," Am. J. Physiol., 227(6):1385-1388. |
| C152 | BRINES et al., 2004, "Erythropoietin mediates tissue protection through an erythropoietin and common β -subunit heteroreceptor," PNAS, Vol. 101(41):14907-14912 |
| C153 | BRIZZI et al., 1991, "Hematopoietic growth factor receptors," Int. J. Cell. Cloning 9:274-300 |
| C154 | BRUNEVAL et al., 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With Erythrocytosis," Blood, 81(6):1593-1597. |
| C155 | BUEMI et al., 2002, "Recombinant human erythropoietin influences revascularization and healing in a rat model of random ischaemic flaps," Acta Derm. Venereol. 82:411-417 |
| C156 | BUNDGAARD and MOLLER, 1981, "Floraseradish peroxidase and microperoxidase. Their purity and binding to serum proteins," J. Histochem. Cytochem. 29(3):331-336 |
| C157 | CALVILLO et al., 2003, "Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling," Proc. Nat. Acad. Sci. USA 100:4802-6 |
| C158 | CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci., 149:40-45. |
| C159 | CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," Proteins 24:394-401 |
| C160 | CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways," Cardiovasc Res. 60(2): 315-325 |
| C161 | CERNEUS and VAN DER ENDE, 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," J Cell Biol. 114(6):1149-1158. |
| C162 | CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," Mol. Brain Res. 81: 29-42 |
| C163 | CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374. |
| C164 | COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067. |
| C165 | COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760. |
| C166 | COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17. |
| C167 | CUNNINGHAM and WELLS, 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," Science 244:1081-1085 |
| C168 | D'ANDREA and GONDA, 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," Exp. Hematol. 28(3):231-243 |
| C169 | D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," J. Clin. Invest. 102(11):1951-1960 |
| C170 | D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," J. Clin. Invest. 86(3):681-687 |
| C171 | DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," Nature 415:175-179 |
| C172 | DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," Biol. Neonate 79(304):228-235 |

EXAMINER

NY14228197v1

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPPE 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

10165-037-999

APPLICATION NO

10/520,140

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

| | | |
|------|--|--|
| C173 | DEGUCHI et al., 1999, "Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker," <i>Bioconjug Chem.</i> 10(1):32-37 | |
| C174 | DEL MASTRO and VENTURI, 1998, "Strategies for the use of epoetin alfa in breast cancer patients," <i>The Oncologist</i> 3:314-318 | |
| C175 | DENIZOT and LANG, 1986, "Rapid colorimetric assay for cell growth and survival - Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability," <i>J. Immunol. Meth.</i> 89:271-277 | |
| C176 | DIAZ-BRINTON and YAMAZAKI, 1998, "Advances and challenges in the prevention and treatment of Alzheimer's disease," <i>Pharm. Res.</i> 15(3):386-98 | |
| C177 | DIETRICH et al., 1993, "Microvascular and neuronal consequences of common carotid artery thrombosis and platelet embolization in rats," <i>J. Neuropathol. Experimental Neurol.</i> 52(4):351-360 | |
| C178 | DISPERSYN et al., 1999, "Cardiomyocyte remodeling during myocardial hibernation and atrial fibrillation: prelude to apoptosis," <i>Cardiovasc. Res.</i> 43(4): 947-957 | |
| C179 | DOBBIN et al., 1989, "Transient blood-brain barrier permeability following profound temporary global ischaemia: An experimental study using ¹⁴ C-AIB," <i>J. of Cerebral Blood Flow Metabolism</i> 9:71-78 | |
| C180 | DONG et al., 1992, "Receptor binding of asialoerythropoietin," <i>J. Cell. Biochem.</i> 48(3):269-276 | |
| C181 | DORDAL et al., 1985, "The Role of Carbohydrate in Erythropoietin Action," <i>Endocrinol.</i> , 116(6):2293-2299. | |
| C182 | DOX et al., 1993, "The Harper Collins Illustrated Medical Dictionary," Harper Collins Publishers, Inc. New York, 1993 | |
| C183 | DUBE et al., 1988, "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function," <i>J. Biol. Chem.</i> , 263(33):17516-17521. | |
| C184 | ECKART, 2002, "Anaemia of critical illness—implications for understanding and treating rHuEPO resistance," <i>Nephrol Dial Transplant</i> 17, Suppl 5, pp. 48-55 | |
| C185 | EGRIE and BROWNE, 2001, "Development and characterization of novel erythropoiesis stimulating protein (NESP)," <i>Nephrol. Dial. Transplant</i> 16 (suppl. 3):3-13 | |
| C186 | EHRENREICH, 2004, "Erythropoietin: a candidate compound for neuroprotection in schizophrenia," <i>Molecular Psychiatry</i> , 9:42-54 | |
| C187 | EHRENREICH, 2004 "A boost for translational neuroscience," <i>Science</i> , Vol. 305:184-185 | |
| C188 | ELLIOTT et al., 1997, "Mapping of the active site of recombinant human erythropoietin," <i>Blood</i> 89(2):493-502 | |
| C189 | EMIR, 2004, "Erythropoietin on <i>bcl-2</i> gene expression in rat cardiac myocytes after traumatic brain injury," <i>Transplantation Proceedings</i> , Vol. 36, pp. 2935-2938 | |
| C190 | ERBAYRAKTAR et al., 2003, "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 100(11):6741-6 | |
| C191 | EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5. | |
| C192 | EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782. | |
| C193 | FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", <i>Blood</i> 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001) | |
| C194 | FARUKI and KISS, 1995, "Erythropoietin, transfusion medicine update, The Institute for Transfusion Medicine, path.upmc.edu/consult/ria/july.1995.html | |
| C195 | FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," <i>Curr. Opin. Neurol.</i> 15(4):483-489 | |
| C196 | FISHBEIN et al., 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," <i>Am. Heart Journal</i> 101(5): 593-600 | |
| C197 | FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," <i>J. Clin. Endocrinol. Metabol.</i> 78(3):753-756 | |

EXAMINER

NY14228197.1

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

10165-037-999

APPLICATION NO

10/520,140

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

| | |
|------|---|
| C198 | FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin action--it takes two to tango, but how?" <i>Endocrinology</i> 143(1):2-10 |
| C199 | FRESHNEY, 1983, "Culture of animal cells," A Manual of Basic Technique, A R. Liss, Inc. NY 1983, pp. 3-4 |
| C200 | FRIDEN, 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," <i>J. Controlled Release</i> 46:117-28 |
| C201 | FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," <i>Am. J. Kidney Disease</i> 26(1), pp. 202-208 |
| C202 | FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," <i>Blood</i> , 73(1):84-89. |
| C203 | FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," <i>Leukemia</i> , 11 (Suppl. 3): 444-445 |
| C204 | FUNG and GREENE, 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," <i>Semin. Immunol.</i> 2:119-128 |
| C205 | GABRIEL et al., 1998, "High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome," <i>J. Trauma</i> 44(2):361-367 |
| C206 | GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," <i>J. Biol. Chem.</i> 269(10):7224-7230 |
| C207 | GARCIA et al., 1996, "Ischemic stroke and incomplete infarction," <i>Stroke</i> , Vol. 27(4):761-765 |
| C208 | GARTHOFF, 1995, "Safety and Efficacy Testing of Hormones and Related Products," The Report and Recommendations of ECVAM Workshop 9, A.I.L.A., 23:699-711 |
| C209 | GENBANK No. M59941, 1994 (Human GM-CSF Receptor β chain) |
| C210 | GOLDBERG et al., 2002, "Erythropoietin mimetics derived from solution phase combinatorial libraries," <i>J. Amer. Chem Soc.</i> 124(4):544-555 |
| C211 | GOLDWASSER et al., 1975, "Erythropoietin: Assay and Study of Its Mode of Action," <i>Methods in Enzymology, Hormone Action Part B, Peptides Hormones</i> , 1975 Academic Press, Vol. 28, pp. 109-121. |
| C212 | GOLDWASSER et al., 1974, "On the Mechanism of Erythropoietin-Induced Differentiation," XIII. The Role of Sialic Acid in Erythropoietin Action, <i>J. Biol. Chem.</i> , 249(13):4202-4206. |
| C213 | GOLDWASSER et al., 1975, "An Assay for Erythropoietin <i>in Vitro</i> at the Millimolar Level," <i>Endo.</i> , 97(2):315-323. |
| C214 | GRASSO et al., 2006, "Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivative," <i>J. Neurosurg. Spine</i> 4(4):310-318 |
| C215 | GRFEN, 1998, "Clomethiazole (Zendra®) in acute ischemic stroke: Basic pharmacology and biochemistry and clinical efficacy," <i>Pharmacol Ther.</i> 80(2):123-147 |
| C216 | GREENBERG et al., 1995, "Congestive heart failure and sleep apnoea-possible mechanisms and effect of CPAP therapy," <i>J. Sleep Res.</i> 4(S1): 130-134 |
| C217 | GREGORY et al., 1999, "GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-x _L expression", <i>Blood</i> 94:87-96 |
| C218 | GRIMM et al., 2002, "HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration," <i>Nature Medicine</i> 8(7):718-724 |
| C219 | GROTZINGER, 2002, "Molecular mechanisms of cytokine receptor activation," <i>Biochim. Biophys. Acta.</i> 1592:215-223 |
| C220 | GRUBER et al., 2002, "The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects <i>in vivo</i> ," <i>J. Biol. Chem.</i> 277(31):27581-27584 |
| C221 | GUNASEKAR et al., 2001, "Mechanisms of the apoptotic and necrotic actions of trimethyltin in cerebellar granule cells," <i>Toxicological Sciences</i> 64:83-89 |
| C222 | HAMMOND et al., 1968, "Production, Utilization and Excretion of Erythropoietin: I. Chronic Anemias. II. Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma," <i>Annals NY Academy of Sciences</i> 149:516-527. |

EXAMINER

NY14228197A1

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

| | | |
|------|--|--|
| C223 | HANAZONO et al., 1995, "Erythropoietin induces tyrosine phosphorylation of the beta chain of the GM-CSF receptor," Biochem. Biophys. Res. Comm. 208(3):1060-1066 | |
| C224 | HANCHER et al., 1974, "Recovery of Erythropoietin from Anemic Sheep Plasma," Biotechnology and Bioengineering 16:1069-1079 | |
| C225 | HANSEN, et al., 2000, "A randomized, blinded placebo controlled, phase II, dose-finding study of ARANESP in patients with lymphoproliferative malignancies," Blood, Vol. 96(11), pp. 155b, Abstr. 4371 | |
| C226 | HARRIS et al., 1992, "Ligand binding properties of the human erythropoietin receptor extracellular domain expressed in <i>Escherichia coli</i> ," J. Biol. Chem. 267(21):15205-15209 | |
| C227 | HARRIS et al., 2000, "Purification and characterization of yeast-expressed erythropoietin (R103A), an erythropoietin antagonist," Blood 96(11, part 2):154b Abstract 4366 | |
| C228 | HARRIS et al., 2001, "Characterization of the yeast-expressed erythropoietin mutant, Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis," Blood, 98(11, part 1):77a Abstract 319 | |
| C229 | HARRIS K. W., 2004, "Signal transduction in myeloid differentiation," Federal Research in Progress database, FRP 03-05, ID No. 136456, Comp & Dist. By NTIS | |
| C230 | HASSAN and FREUND, 1995, "Review of megakaryoblastic cell lines -Characteristic biological features of human megakaryoblastic leukaemia cell lines," Leuk. Res. 19(9):589-594 | |
| C231 | HÖRKKÖ et al., 1992, "Carbamylation-induced alterations in low-density lipoprotein metabolism," Kidney Int. 41(5):1175-1181 | |
| C232 | HORTON et al., 1991, "Von Hippel-Lindau Disease and Erythrocytosis: Radioimmunoassay of Erythropoietin in Cyst Fluid From a Brainstem Hemangioblastoma," Neurology, 41:753-754. | |
| C233 | HUWYLER and PARDRIDGE, 1998, "Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat brain capillaries," J. Neurochem. 70(2):883-886 | |
| C234 | HUWYLER et al., 1997, "Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat," J. Pharmacol Exp Ther. 282(3):1541-1546. | |
| C235 | IMADA et al., 1992, "Interleukin-2 (IL-2) induces erythroid differentiation and tyrosine phosphorylation in ELM-1 cells transfected with a human IL-2 receptor beta chain cDNA," Biochem. Biophys. Res. Commun. 188(1):352-357 | |
| C236 | IMAI et al., 1990, "Physicochemical and Biological Characterization of Asialoerythropoietin," Eur. J. Biochem., 194:457-462. | |
| C237 | ISEKI et al., 1996, "Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients," Nephron 72:30-36 | |
| C238 | ITO et al., 1990, "Cloning of an interleukin-3 receptor gene: a member of a distinct receptor gene family," Science 247:324-327 | |
| C239 | JACOBS et al., 1985, "Isolation and characterization of genomic and cDNA clones of human erythropoietin," Nature 313(28):806-810 | |
| C240 | JENKINS et al., 1999, "A cell type-specific constitutive point mutant of the common β -subunit of the human granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 receptors requires the GM-CSF receptor α -subunit for activation," J. Biol. Chem. 274(13):8669-8677 | |
| C241 | JIANG et al., 1996, "Delayed intravenous administration of basic fibroblast growth factor (bFGF) reduces infarct volume in a model of focal cerebral ischemia/reperfusion in the rat," J. Neurological Sciences 139:173-179 | |
| C242 | JONES et al., 1990, "Human erythropoietin receptor: cloning, expression, and biologic characterization," Blood 76(1):31-35 | |
| C243 | JOSS et al., 1996, "Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung," Hum. Gene Ther. 7(13):1555-1566 | |
| C244 | JOSSE et al., 1999, "Human serum paraoxonase (PON1): Identification of essential amino acid residues by group-selective labelling and site-directed mutagenesis," Chem. Biol. Interact. 119-120:71-78 | |

EXAMINER

NYI-4228197-1

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

| | |
|-----------------|----------------|
| ATTY DOCKET NO | APPLICATION NO |
| 10165-037-999 | 10/520,140 |
| APPLICANT | |
| Brines et al. | |
| FILING DATE | ART UNIT |
| January 3, 2005 | 1647 |

| | |
|------|--|
| C245 | JOSSE et al., 1999, "Tryptophan residue(s) as major components of the human serum paraoxonase active site," Chem. Biol. Interact. 119-120:79-84 |
| C246 | JUBINSKY et al., 1996, "The β c component of the granulocyte-macrophage colony-stimulating factor (GM-CSF)/interleukin 3 (IL-3)/IL-5 receptor interacts with a hybrid GM-CSF/erythropoietin receptor to influence proliferation and β -globin mRNA expression," Mol. Med. 2(6):766-773 |
| C247 | JUBINSKY et al., 1997, "The β chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor," Blood 90(5):1867-1873 |
| C248 | JUUL et al., 1998, "Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus", Early Human Devel. 52(3):235-249 |
| C249 | JUUL et al., 2001, "Recombinant erythropoietin (EPO) crosses the blood brain barrier (BBB) in preterm fetal sheep", Soc. for Neuroscience Abstracts 27(1):929 (31st Annual Meeting of the Society for Neuroscience, San Diego, CA Nov. 10-15, 2001) |
| C250 | JUUL, S. 2002, "Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage," Acta Paediatr. Supp. 438:36-42 |
| C251 | KANG et al., 1994, "Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor," Drug Metab. Dispos. 22(1):99-105 |
| C252 | KAWASAKI et al., 2001, "Structural analysis of sulfated N-linked oligosaccharides in erythropoietin," Glycobiology 11(12):1043-1049 |
| C253 | KAYE DM et al., 2003, Feasibility and short-term efficacy of percutaneous mitral annular reduction for the therapy of heart failure-induced mitral regurgitation. Circulation 108:1795-1797 |
| C254 | KEIGHLEY, 1968, "Further Experiences with Assays, Units, and Standards of Erythropoietin," Annals New York Acad. Sci., 149:18-24. |
| C255 | KESWANI et al., 2004, "A novel endogenous erythropoietin mediated pathway prevents axonal degeneration," Ann. Neurol. Vol. 56(6):815-826 |
| C256 | KIRITO et al., 2002, "Identification of the human erythropoietin receptor region required for Stat1 and Stat3 activation," Blood 99(1):102-110 |
| C257 | KISHIMOTO and TAVASSOLI, 1987, "Transendothelial transport (transcytosis) of iron-transferrin complex in the rat liver," Am. J. Anat. 178:241-249. |
| C258 | KITAMURA et al., 1989, "Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1," Blood 73(2):375-80 |
| C259 | KOHAMA et al., 2000, "Large Uterine Myoma with Erythropoietin Messenger RNA and Erythrocytosis," Obstetrics and Gynecology, 96(5):826-828. |
| C260 | KRAFTE-JACOBS et al., 1996, "Circulating erythropoietin and interleukin-6 concentrations increase in critically ill children with sepsis and septic shock," Crit. Care Med. 24(9):1455-1459 |
| C261 | KUMRAL et al., 2004, "Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rat," Behavioral Brain Research, Vol. 153:77-86 |
| C262 | KUROIWA et al., 1985, "The biphasic opening of the blood-brain barrier to proteins following temporary middle cerebral artery occlusion," Acta Neuropathologica 68:122-129 |
| C263 | LAI et al., 1996, "The molecular role of the common gamma ₂ subunit in signal transduction reveals functional asymmetry within multimeric cytokine receptor complexes," Proc. Natl. Acad. Sci. USA 93:231-235 |
| C264 | LEE et al. 1998, "Conditional lineage ablation to model human diseases," Proc. Natl. Acad. Sci. USA 95:11371-11376 |
| C265 | LEITGEB et al., 1994, "Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin," Cancer, 73(10):2535-2542 |
| C266 | LEIST et al., 2004, "Derivatives of erythropoietin that are tissue protective but not erythropoietic," Science, Vol. 305, pp. 239-242 |
| C267 | LEWIS et al., 1996, "Molecular characterization of the 7q deletion in myeloid disorders," Br. J. Haematol. 93:75-80 |

EXAMINER
NY1-4228197v1

DATE CONSIDERED

*EXAMINER Initial of reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

| | | |
|------|--|--|
| C268 | LEWIS et al., 2004, "Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid progenitor cell proliferation and differentiation <i>in vitro</i> ," Exp. Hematol. 32:36-44 | |
| C269 | LI et al., 1996, "Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses", Pediatr. Res. 40(3):376-380 | |
| C270 | LINSLEY et al., 1994, "Applications of electrospray mass spectrometry to erythropoietin N- and O-linked glycans," Anal. Biochem. 219:207-217 | |
| C271 | LIU et al., 1994, "Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the Grb2 recognition site of Shc." Mol. Cell. Biol. 14(10):6926-6935 | |
| C272 | LIU et al., 1996, "Transgenic mice containing the human erythropoietin receptor gene exhibit correct hematopoietic and neural expression", Proc. Assoc. Am. Physicians 108(6):449-454 | |
| C273 | LIVNAH et al., 1999, "Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation," Science 283:987-990 | |
| C274 | LOBERG et al., 1993, "Neuronal uptake of plasma proteins after transient cerebral ischemia/hypoxia," APMS 101:777-783 | |
| C275 | LOWY et al., 1960, "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions," Nature, 185:102-103. | |
| C276 | LU et al., 2005, "Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury," J. of Neurotrauma, Vol. 22(9), pp. 1011-1017 | |
| C277 | MAGNANT et al., 2001, "Erythropoietin expression in primary rat Sertoli and peritubular myoid cells," Blood 98(9):2872-2874 | |
| C278 | MAITANI et al., 1996, "Oral administration of recombinant human erythropoietin in liposomes in rats: influence of lipid composition and size of liposomes on bioavailability", J. Pharm. Sci. 85(4):440-45 | |
| C279 | MASSAGUE, 1987, "The TGF-beta family of growth and differentiation factors," Cell 49:437-438 | |
| C280 | MATSUYAMA et al., 2000, "Erythrocytosis Caused by an Erythropoietin-Producing Hepatocellular Carcinoma," J. Surg. Oncology, 75:197-202. | |
| C281 | MATTHEWS et al., 1996, "A sequential dimerization mechanism for erythropoietin receptor activation," Proc. Natl. Acad. Sci. USA 93:9471-9476 | |
| C282 | McCLURE et al., 2001, "GM-CSF binding to its receptor induces oligomerisation of the common beta-subunit," Cytokine 13(4):240-243 | |
| C283 | MEANS and KRANTZ, 1996, "Inhibition of human erythroid colony-forming units by interferons α and β : differing mechanisms despite shared receptor," Exp. Hematol. 24:204-208 | |
| C284 | MENZIES and ELLIS, 1990 "Intestinal obstruction from adhesions - how big is the problem?, Ann. R. Coll. Surg. Engl. 72:60-63 | |
| C285 | MENZIES et al., 1996, "Extravasation of albumin in ischaemia brain oedema," Acta Neurochirurgica, Suppl. 51:220-222 | |
| C286 | MIONI et al., 1992, "Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells", Acta Endocrinologica 127:459-465 | |
| C287 | MIU et al., 2004, "Have no fear, erythropoietin is here, erythropoietin protects fear conditioning performances after functional inactivation of the amygdala," Behavioral Brain Research, Vol. 155, pp. 223-229 | |
| C288 | MIYAKE et al., 1977, "Purification of Human Erythropoietin," J. Biol. Chem., 252(15):5558-5564. | |
| C289 | MOGENSEN et al., 2004, Erythropoietin improves place learning in fimbria-fornix-transected rats and modifies the search pattern of normal rats," Pharmacology, Biochemistry and Behavior, Vol. 77:381-390 | |
| C290 | MORELL et al., 1968, "Physical and Chemical Studies on Ceruloplasmin," Metabolic Studies on Saliv Acid-Free Ceruloplasmin In Vivo, J. Biol. Chem., 243(1):155-159. | |
| C291 | MUN and GOLPER, 2000, "Impaired biological activity of erythropoietin by cyanate carbamylation," Blood Purif. 18:13-17 | |

EXAMINER
NY14228197v1

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

| | | |
|------|--|--|
| C292 | MURAKAMI et al., 1991, "Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family," Proc. Natl. Acad. Sci. USA 88(24):11349-11353 | |
| C293 | MURRAY, 1996, Harpers Illustrated Biochemistry 26 th ed. pp. 524-526, McGraw-Hill Co. | |
| C294 | NAGAO et al., 1992, "Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor," Biochem. Biophys. Res. Comm. 188(2):888-897 | |
| C295 | NAKAMURA et al., 1998, "Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients", Am. J. Med. Sci. 315(3):199-201 | |
| C296 | NARANDA et al., 2002, "Activation of erythropoietin receptor through a novel extracellular binding site," Endocrinology 143(6):2293-2302 | |
| C297 | NATHAN, 1994, "Studies of hybrid hematopoietic growth factor receptors," Stem Cells 12 (Suppl 1):27-35 | |
| C298 | NESTLER et al., 1985, "Stimulation of rat ovarian cell steroidogenesis by high density lipoproteins modified with tetranitromethane," J. Biol. Chem. 260(12):7316-21 | |
| C299 | NIMTZ and CONRADT, 1993, "Characterization of a phosphorylated oligosaccharide from erythropoietin expressed in recombinant BHK cells," Glycoconj. J. 10(4):259, Abstr. S6.7 | |
| C300 | NOGUCHI et al., 1991, "Cloning of the human erythropoietin receptor gene," Blood 78(10):2548-2556 | |
| C301 | OHTA et al., 2001, "Selective glycopeptide mapping of erythropoietin by on-line high-performance liquid chromatography-electrospray ionization mass spectrometry," J. Chromatography A, 910:1-11 | |
| C302 | OKADA et al., 1996, "Erythropoietin stimulates proliferation of rat-cultured gastric mucosal cells," Digestion 57:328-332 | |
| C303 | OPITZ et al., 1995, "Arrhythmias and Death After Coronary Artery Occlusion in the Rat," Circulation. 92(2):253-261 | |
| C304 | OPITZ et al., 1998, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat: increased electrical stability independent of myocardial salvage," J. Am. Coll. Cardiol. 32(1): 261-267 | |
| C305 | PAGE et al., 1996, "A sensitive human cell line based bioassay for megakaryocyte growth and development factor or thrombopoietin," Cytokine 8(1):66-69 | |
| C306 | PANTOLIANO et al., 1987, "Protein engineering of subtilisin BPN': Enhanced stabilization through the introduction of two cysteines to form a disulfide bond," Biochemistry 26:2077-2082 | |
| C307 | PARDRIDGE, 1998, "CNS drug design based on principles of blood-brain barrier transport," J Neurochem. 70:1781-92. | |
| C308 | PARK and HONG, 1997, "Development of an in vitro bioassay system for human thrombopoietin by constructing a recombinant murine cell line expressing human thrombopoietin receptor," Mol. Cells. 7(6):699-704 | |
| C309 | PAZUR et al., 2000, "Oligosaccharides as immuno-determinants of erythropoietin for two sets of anti-carbohydrates antibodies," J. Protein Chem. Vol. 19(8):631-635 | |
| C310 | PEDERSEN et al., 1995, "The interaction of beta 2-microglobulin (β 2m) with mouse class I major histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta 2m," Eur. J. Immunol. 25:1609-16 | |
| C311 | PENG et al., 2000, "HPLC/ESI MS and MALDI/TOF MS analysis of microheterogeneity of the N-linked oligosaccharides of recombinant human erythropoietin," Yao Xue Bao (Acta Pharmaceutica Sinica) 35(10):770-773 (w/ English abstract) | |
| C312 | PENNY and FORGET, 1991, "Genomic organization of the human erythropoietin receptor gene," Genomics 11(4):974-980 | |
| C313 | PETITO, 1979, "Early and late mechanisms of increased vascular permeability following experimental cerebral infarction," J. Neuropathol. Exp. Neurol. 38(3):222-34 | |
| C314 | PFEFFER et al., 1991, Progressive ventricular remodeling in rat with myocardial infarction. Am. J. Physiol. 260(5 Pt 2): H1406-1414 | |

EXAMINER

NY1-4228197v1

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPPE 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO

10165-037-999

APPLICATION NO

10/520,140

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

| | | |
|------|---|--|
| C315 | PHYSICIANS' DESK REFERENCE, 1995, 49 th Edition (Medical Economics Data Production Company, Montvale, NJ), pp. 1765-1769 | |
| C316 | PHYSICIANS' DESK REFERENCE, 2000 (Medical Economics Company, Inc. Montvale, NJ), pp. 519-525 and 2125-2131 | |
| C317 | PILBEAM et al., 1993, "Comparison of the effects of various lengths of synthetic human parathyroid hormone-related peptide (hPTHrP) of malignancy on bone resorption and formation in organ culture," Bone 14:717-720 | |
| C318 | PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol. Chem. 246(4):939-45 | |
| C319 | PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," Diabetes 32:1087-1091 | |
| C320 | QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," J. Biol. Chem. 273(18):11173-11176 | |
| C321 | REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" Current Pharmaceutical Design, 9:75-82 | |
| C322 | REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," Science 283:990-993 | |
| C323 | ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42 | |
| C324 | ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" Am. J. Physiol. 271(1 pt. 2):R244-R253 | |
| C325 | ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurointracarboxylic acid," Vision Res., 37(24):3445-3451 | |
| C326 | RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoproteinase digestion of erythropoietin by affinity high-performance capillary electrophoresis," Anal. Chem. 65(14):1834-1842 | |
| C327 | RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," Anal. Chemistry, 67(8):1442-1452 | |
| C328 | SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," Acta Neurochirurgica, Suppl. 51:186-188 | |
| C329 | SCHUSSLER et al., 1998, "Erythropoietin and obstetrical influences," Zeitschrift fur Geburtshilfe und Neonatologie 202(2):64-68 (With English Abstract) | |
| C330 | SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," Blood 96(4):1588-1590 | |
| C331 | SHIKAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines," Blood 88(2):455-464 | |
| C332 | SHULMAN et al., 2002, "Current drug treatment of Sepsis," Hospital Pharmacist 9:97-107 | |
| C333 | SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone marrow," J Ultrastruct Res. 88(1):18-29 | |
| C334 | STARK, 1967, "Modification of proteins with cyanate" Methods Enzymol. 11:590-594 | |
| C335 | STENESH, J., 1989, Dictionary of Biochemistry And Molecular Biology, 2 nd Ed., New York. John Wiley & Sons, p. 122, p. 508 | |
| C336 | STURM et al., 2005, "Recombinant human erythropoietin: effects on frataxin expression in vitro," European J. of Clinical Investigation, Vol. 35, pp. 711-717 | |
| C337 | SUZUKI et al., 1983, "The effects of 5-minute ischemia in Mongolian gerbils: 1. Blood-brain barrier, cerebral blood flow, and local cerebral glucose utilization changes," Acta Neuropathologica (Berl) 60:207-216 | |

EXAMINER

NY1-4228197-1

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-----------------|----------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO | APPLICATION NO |
| | 10165-037-999 | 10/520.140 |
| | APPLICANT | |
| | Brines et al. | |
| | FILING DATE | ART UNIT |
| | January 3, 2005 | 1647 |

| | | |
|------|--|--|
| C338 | SWEENEY et al., 1995, "Cellular mechanisms involved in brain ischemia," Can. J. Physiol. Pharmacol. Vol. 73:1525-1535 | |
| C339 | SWISS PROT ACCESSION No. P32927, October 1, 1993 (IL3 RB Human) | |
| C340 | SYED et al., 1998, "Efficiency of signaling through cytokine receptors depends critically on receptor orientation," Nature 395:511-516 | |
| C341 | TAKAHASHI, 1977, "The reactions of phenylglyoxal and related reagents with amino acids," J. Biochem., Vol. 81:395-402 | |
| C342 | TEMPLE et al., 1995, "Recombinant erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis," Nephrology Dialysis Transplantation, Vol. 10:1733-1738 | |
| C343 | TEIEN et al., 1995, Doppler evaluation of severity of mitral regurgitation: relation to pulmonary venous blood flow patterns in an animal study. J. Am. Coll. Cardiol. 25(1): 264-268 | |
| C344 | TOJO et al., 1987, "Identification of erythropoietin receptors on fetal liver erythroid cells," Biochem. Biophys. Res. Commun. 148(1):443-448 | |
| C345 | URENA, 2002, "Treatment of anemia in chronic renal failure by a long-active activator of erythropoiesis," Press Medicale 31(11):505-514 (w/ English abstract) | |
| C346 | VAN DER MEER et al., 2005, "Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction," JACC, Vol. 46(11) pp. 125-133 | |
| C347 | VANSTEENKISTE et al., 2003, "Darbepoietin alfa: a new approach to the treatment of chemotherapy-induced anaemia," Expert Opin. Biol. Ther. Vol. 3(3):501-508 | |
| C348 | VEZZANI et al., 1999, "Interleukin-1 β immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: Functional evidence for enhancement of electrographic seizures," J. Neurosci. 19(12):5054-65 | |
| C349 | VEZZANI et al., 1986, "Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures but not neurotoxicity induced in rats by quinolinic acid: Electroencephalographic, behavioral and histological assessments," J. Pharmacol. Exp. Ther. 239(1):256-263 | |
| C350 | VUKICEVIC et al., 1996, "Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7)," PNAS USA 93:9021-9026 | |
| C351 | WAUBEN-PENRIS et al., 1988, "The release of iron by Sertoli cells in culture," Biol. Reprod. 38:1105-1113 | |
| C352 | WELLS, 1990, "Additivity of mutational effects in proteins," Biochemistry 29(37):8509-8517 | |
| C353 | WEN et al., 1994, "Erythropoietin structure-function relationships," J. Biol. Chem. 269(36):22839-22846 | |
| C354 | WIDNESS et al., 1995, "Erythropoietin transplacental passage-Review of animal studies," J. Perinat. Med. 23: 61-70 | |
| C355 | WILLIAMSON et al., 1993, "Protein and lipid kinase activation cascades in interleukin-2 receptor signalling," Semin. Immunol. 5(5):337-344 | |
| C356 | WINKELMANN et al., 1990, "The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p," Blood 76(1):24-30 | |
| C357 | WIT et al., 1992, "Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction," Circulation 85 Suppl. 1:1-32-142 | |
| C358 | WOJCZOWSKI and CASLAKE, 1989, "Biotinylated recombinant human erythropoietins: bioactivity and utility as receptor ligands," Blood, Vol. 74(3):952-958 | |
| C359 | WOLF et al., 1997, "Erythropoietin administration increases production and reactivity of platelets in dogs," Thromb. Haemost. 78:1505-1509 | |
| C360 | WU and PARDRIDGE, 1996, "Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system," J Pharmacol Exp Ther. 279(1):77-83 | |

EXAMINER
NYI-4228197.v1

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

| | | |
|------|--|--|
| C361 | XIAO et al., 1998, "Fibrinogen deficiency is compatible with the development of atherosclerosis in mice," J. Clin. Invest. 101(5):1184-1194 | |
| C362 | YAMAMURA et al., 1992, "Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor," EMBO J. 11(13):4909-4915 | |
| C363 | YANG et al., 1994, "Reperfusion-induced injury to the blood-brain barrier after middle-cerebral artery occlusion in rats," Stroke, Vol. 25(8):1658-1665 | |
| C364 | YET et al., 1993, "The extracytoplasmic domain of the erythropoietin receptor forms a monomeric complex with erythropoietin," Blood 82(6):1713-1719 | |
| C365 | YOSHIMURA et al., 1995, "A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors," EMBO J. 14(12):2816-2826 | |
| C366 | YOSHIMURA et al., 1996, "Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway," EMBO J. 15(5):1055-1063 | |
| C367 | YOSHIMURA et al., 1996, "Physician Education: The Erythropoietin Receptor and Signal Transduction," Oncologist 1(5):337-339 | |
| C368 | ZENG, 1991, "Lysine modification of metallothionein by carbamylation and guanidination," Methods Enzymol. 205:433-437 | |
| C369 | ZHANG et al., 2006, "Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms," J. Neurosci. Res. 83:1241-51 | |
| C370 | ZHU et al., 2002, "Detecting and responding to hypoxia," Nephrol. Dial. Transplant. 17 Suppl 1:3-7 | |
| C371 | Office Action, Application No. 09/547,220, date mailed: May 8, 2002 | |
| C372 | Office Action, Application No. 09/547,220, date mailed: June 13, 2002 | |
| C373 | Office Action, Application No. 09/547,220, date mailed: October 22, 2002 | |
| C374 | Office Action, Application No. 09/547,220, date mailed: January 28, 2003 | |
| C375 | Office Action, Application No. 09/547,220, date mailed: December 2, 2003 | |
| C376 | Office Action, Application No. 09/547,220, date mailed: September 22, 2004 | |
| C377 | Office Action, Application No. 09/547,220, date mailed: June 6, 2005 | |
| C378 | Office Action, Application No. 09/547,220, date mailed: February 22, 2006 | |
| C379 | Office Action, Application No. 09/547,220, date mailed: August 31, 2006 | |
| C380 | Notice of Abandonment, Application No. 09/547,220, date mailed: June 26, 2007 | |
| C381 | Office Action, Application No. 09/716,960, date mailed: August 26, 2002 | |
| C382 | Office Action, Application No. 09/716,960, date mailed: July 25, 2003 | |
| C383 | Office Action, Application No. 09/716,960, date mailed: March 8, 2004 | |
| C384 | Office Action, Application No. 09/716,960, date mailed: September 16, 2004 | |
| C385 | Office Action, Application No. 09/716,960, date mailed: January 19, 2005 | |
| C386 | Office Action, Application No. 09/716,960, date mailed: May 8, 2006 | |
| C387 | Office Action, Application No. 09/716,960, date mailed: February 1, 2007 | |
| C388 | Office Action, Application No. 09/716,960, date mailed: October 16, 2007 | |
| C389 | Office Action, Application No. 09/716,960, date mailed: December 6, 2007 | |

EXAMINER
NYI-4228197.1

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO

10165-037-999

APPLICATION NO

10/520,140

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

| | | |
|------|--|--|
| C390 | Notice of Allowance, Application No. 09/716,960, date mailed: February 21, 2008 | |
| C391 | Office Action, Application No. 09/717,057, date mailed: May 17, 2002 | |
| C392 | Office Action, Application No. 09/717,057, date mailed: November 1, 2002 | |
| C393 | Office Action, Application No. 09/717,057, date mailed: July 15, 2003 | |
| C394 | Office Action, Application No. 09/717,057, date mailed: April 5, 2004 | |
| C395 | Office Action, Application No. 09/717,057, date mailed: October 26, 2004 | |
| C396 | Office Action, Application No. 09/717,057, date mailed: April 5, 2005 | |
| C397 | Office Action, Application No. 09/717,057, date mailed: January 9, 2006 | |
| C398 | Office Action, Application No. 09/717,057, date mailed: October 10, 2006 | |
| C399 | Notice of Allowance, Application No. 09/717,057, date mailed: May 18, 2007 | |
| C400 | Office Action, Application No. 09/717,053, date mailed: May 13, 2002 | |
| C401 | Office Action, Application No. 09/717,053, date mailed: July 16, 2002 | |
| C402 | Office Action, Application No. 09/717,053, date mailed: April 9, 2003 | |
| C403 | Office Action, Application No. 09/717,053, date mailed: October 15, 2003 | |
| C404 | Office Action, Application No. 09/717,053, date mailed: April 20, 2004 | |
| C405 | Office Action, Application No. 09/717,053, date mailed: May 3, 2005 | |
| C406 | Office Action, Application No. 09/717,053, date mailed: January 20, 2006 | |
| C407 | Office Action, Application No. 09/717,053, date mailed: October 24, 2006 | |
| C408 | Notice of Allowance, Application No. 09/717,053, date mailed: April 26, 2007 | |
| C409 | Office Action, Application No. 09/753,132, date mailed: January 25, 2002 | |
| C410 | Office Action, Application No. 10/185,841, date mailed: April 28, 2005 | |
| C411 | Office Action, Application No. 10/185,841, date mailed: January 18, 2006 | |
| C412 | Office Action, Application No. 10/185,841, date mailed: October 5, 2006 | |
| C413 | Office Action, Application No. 10/185,841, date mailed: June 27, 2007 | |
| C414 | Interview Summary, Application No. 10/185,841, date mailed: February 27, 2008 | |
| C415 | Office Action, Application No. 10/185,841, date mailed: January 9, 2009 | |
| C416 | Notice of Allowance, Application No. 10/185,841, date mailed: April 10, 2009 | |
| C417 | Notice of Allowance, Application No. 10/185,841, date mailed: October 22, 2009 | |
| C418 | Office Action, Application No. 10/188,905, date mailed: August 22, 2005 | |
| C419 | Office Action, Application No. 10/188,905, date mailed: March 21, 2006 | |
| C420 | Office Action, Application No. 10/188,905, date mailed: December 7, 2006 | |
| C421 | Office Action, Application No. 10/188,905, date mailed: May 28, 2008 (Interview Summary 5/21/08) | |
| C422 | Office Action, Application No. 10/188,905, date mailed: October 15, 2008 | |

EXAMINER
NY1-4228197v1

DATE CONSIDERED

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

| | | |
|------|---|--|
| C423 | Office Action, Application No. 10/188,905, date mailed: February 12, 2009 (Interview Summary 2/04/09) | |
| C424 | Office Action, Application No. 10/351,640, date mailed: December 13, 2005 | |
| C425 | Office Action, Application No. 10/351,640, date mailed: August 28, 2006 | |
| C426 | Office Action, Application No. 10/351,640, date mailed: June 5, 2007 | |
| C427 | Office Action, Application No. 10/351,640, date mailed: September 19, 2008 | |
| C428 | Office Action, Application No. 10/612,665 date mailed: June 20, 2006 | |
| C429 | Office Action, Application No. 10/612,665 date mailed: February 23, 2007 | |
| C430 | Office Action, Application No. 10/612,665 date mailed: December 31, 2007 | |
| C431 | Office Action, Application No. 10/612,665 date mailed: December 11, 2008 | |
| C432 | Office Action, Application No. 11/880,275, date mailed: May 22, 2009 | |
| C433 | Office Action, Application No. 11/881,759, date mailed: December 12, 2007 | |
| C434 | Office Action, Application No. 11/881,759, date mailed: July 18, 2008 | |
| C435 | Office Action, Application No. 11/881,759, date mailed: September 24, 2008 | |
| C436 | Office Action, Application No. 11/881,759, date mailed: July 21, 2009 | |
| C437 | Office Action, Application No. 11/893,294, date mailed: June 16, 2008 | |
| C438 | Office Action, Application No. 11/893,294, date mailed: October 10, 2008 | |
| C439 | Office Action, Application No. 11/893,294, date mailed: February 2, 2009 | |
| C440 | Office Action, Application No. 10/188,905, date mailed: November 12, 2009 | |
| C441 | Chezzi et al., 2004, "Erythropoietin as an antiapoptotic, tissue protective cytokine | |
| C442 | International Search Report for PCT/US00/10019, mailed August 30, 2000 | |
| C443 | LINDAHL, 1980, "The contributions of erythropoietic and nonerythropoietic haem turnover to the early labile peak of endogenous CO formation in man," Scand. J. Haematol. Apr 24 (4): 271-80 | |
| C444 | SALINSKA et al., 2005, "The role of excitotoxicity in neurodegeneration." Folia Neuropath., 43(4):322-339 | |
| C445 | SEGURA-AGUILAR et al., 2004, "Neurotoxins and neurotoxic species implicated in neurodegeneration." Neurotox. Res., 6(7,8):615-630 | |
| C446 | WANG et al., 2005, "Kainic acid-mediated excitotoxicity as a model for neurodegeneration." Molec. Neurobiol., 31(1-3): 3-16 | |
| C447 | TRIST, 2000, "Excitatory amino acid agonists and antagonists: pharmacology and therapeutic applications." Pharmaceutica Acta Helvetica, 74:221-229 | |
| C448 | Written Opinion for PCT/US00/10019, mailed August 16, 2001 | |
| C449 | Office Action, Application No. 10/351,640, date mailed: July 7, 2009 | |
| C450 | Office Action, Application No. 11/893,294, date mailed: August 13, 2009 | |

EXAMINER

NY-4228197v1

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.